Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sterling Biotech Case:...

    Sterling Biotech Case: Court asks ED reply on Gagan Dhawan bail plea

    Written by Ruby Khatun Khatun Published On 2017-11-26T10:50:20+05:30  |  Updated On 26 Nov 2017 10:50 AM IST
    Sterling Biotech Case: Court asks ED reply on Gagan Dhawan bail plea

    New Delhi: A city court sought the response from the Enforcement Directorate on an application filed by Delhi-based businessman Gagan Dhawan seeking bail in a Rs 5,000-crore money laundering case.


    Additional Sessions Judge Sidharth Sharma directed the agency to file its reply by November 29 when it will hear the matter.


    In his application, the accused, who is currently in the judicial custody, sought the relief saying he was not required for further investigation and no purpose will be served by keeping him in custody.


    Dhawan, arrested on November 1, was sent to custody on November 15 by the court after Rana had said he was not needed for further custodial interrogation.

    The ED had alleged that Dhawan had facilitated the directors of Gujarat-based pharma firm Sterling Biotech Ltd (SBL) in the purchase of several properties and helped in misuse and diversion of the credit facilities of several banks totaling Rs 5,000 crore.

    "Rs 1.5 crore was received by the accused from SBL group. Prior to that, the amount of bank loans was rotated in various group companies of SBL group," according to the agency.

    The lower court had on November 14 issued non-bailable warrants against two other persons -- SBL directors Nitin and Chetan Sandesara. The agency told the court that Chetan may have left the country.




    Read also: Non-bailable warrants issued against Sterling Biotech directors in Rs 5,000 crore fraud case




    Dhawan was arrested in an alleged bank fraud case involving Sterling Biotech Ltd under sections of the Prevention of Money Laundering Act (PMLA).

    The firm and Dhawan were also being probed by the ED for allegedly bribing senior Income Tax department officials in an earlier criminal complaint.

    The CBI had recently booked Sterling Biotech, its directors Chetan Jayantilal Sandesara, Dipti Chetan Sandesara, Rajbhushan Omprakash Dixit, Nitin Jayantilal Sandesara and Vilas Joshi, chartered accountant Hemant Hathi, former director Andhra Bank Anup Garg and some unidentified persons in connection with the alleged bank fraud case.



    Read also: CBI FIR against Sterling Biotech for Rs 5,000 cr loan default

    It had alleged that the company had taken loans of over Rs 5,000 crore from a consortium led by Andhra Bank which had turned into non-performing assets.
    The FIR had also alleged that the total pending dues of the group companies were Rs 5,383 crore as on December 31, 2016. The ED had taken a cognizance of this FIR to file a money laundering case against them.

    bail pleabank fraud casebusinessmanCBI)Chetan SandesaraCourtcustodial interrogationEDFIRGagan DhawanIncome Tax DepartmentJudge Sidharth Sharmajudicial custodymoney laundering caseNitin SandesaraPrevention of Money Laundering ActSterling Biotech
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok